Pzena Investment Management LLC Sells 714,108 Shares of Fresenius Medical Care AG & Co. KGaA $FMS

Pzena Investment Management LLC lessened its position in Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) by 4.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 14,662,982 shares of the company’s stock after selling 714,108 shares during the period. Fresenius Medical Care AG & Co. KGaA comprises 1.4% of Pzena Investment Management LLC’s portfolio, making the stock its 25th largest holding. Pzena Investment Management LLC’s holdings in Fresenius Medical Care AG & Co. KGaA were worth $418,921,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Millennium Management LLC lifted its stake in shares of Fresenius Medical Care AG & Co. KGaA by 50.0% in the first quarter. Millennium Management LLC now owns 1,083,602 shares of the company’s stock worth $26,982,000 after buying an additional 361,364 shares in the last quarter. Todd Asset Management LLC bought a new position in shares of Fresenius Medical Care AG & Co. KGaA in the first quarter worth approximately $12,009,000. Hennessy Advisors Inc. bought a new position in shares of Fresenius Medical Care AG & Co. KGaA in the second quarter worth approximately $11,479,000. Northern Trust Corp lifted its stake in shares of Fresenius Medical Care AG & Co. KGaA by 5.0% in the first quarter. Northern Trust Corp now owns 380,251 shares of the company’s stock worth $9,468,000 after buying an additional 18,061 shares in the last quarter. Finally, Teachers Retirement System of The State of Kentucky bought a new position in shares of Fresenius Medical Care AG & Co. KGaA in the first quarter worth approximately $7,420,000. Institutional investors own 8.37% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Wall Street Zen downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 5th. Morgan Stanley restated an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday, August 12th. UBS Group restated a “sell” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday, September 2nd. Zacks Research upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 6th. Finally, Weiss Ratings upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $27.80.

Fresenius Medical Care AG & Co. KGaA Stock Down 1.4%

Shares of Fresenius Medical Care AG & Co. KGaA stock opened at $26.78 on Monday. Fresenius Medical Care AG & Co. KGaA has a twelve month low of $18.94 and a twelve month high of $30.46. The company has a market cap of $15.71 billion, a price-to-earnings ratio of 21.95, a price-to-earnings-growth ratio of 0.61 and a beta of 0.92. The company has a quick ratio of 1.08, a current ratio of 1.44 and a debt-to-equity ratio of 0.44. The company’s 50 day moving average is $25.33 and its 200 day moving average is $26.24.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last announced its earnings results on Tuesday, August 5th. The company reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of $0.50 by $0.02. Fresenius Medical Care AG & Co. KGaA had a net margin of 3.39% and a return on equity of 6.75%. The business had revenue of $5.54 billion during the quarter, compared to analysts’ expectations of $5 billion. Research analysts anticipate that Fresenius Medical Care AG & Co. KGaA will post 1.51 EPS for the current year.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.